Kawasaki Disease in Mongolia: Results From 2 Nationwide Retrospective Surveys, 1996–2008

Dambadarjaa Davaalkham1, Yosikazu Nakamura2, Davaakhuu Baigalmaa3, Gombojav Davaa1, Ochir Chimedsuren1, Nyamjav Sumberzul4, Tsrenkhuu Lkhagvasuren4, Ritei Uehara2, Hiroshi Yanagawa2, and Tomisaku Kawasaki5

1Department of Epidemiology and Biostatistics, School of Public Health, Health Sciences University of Mongolia, Ulaanbaatar, Mongolia
2Department of Public Health, Jichi Medical University, Shimotsuke, Japan
3Department of Surveillance and Response, National Center for Communicable Diseases, Ulaanbaatar, Mongolia
4Health Sciences University of Mongolia, Ulaanbaatar, Mongolia
5Japanese Kawasaki Disease Research Center, Tokyo, Japan

Received September 22, 2010; accepted March 2, 2011; released online June 18, 2011

ABSTRACT

Background: Kawasaki disease (KD) has been reported in many countries. However, the incidence of KD in Mongolia is not known. This is the first report of incident cases of KD in Mongolia, which were identified using data from 2 nationwide surveys.

Methods: Two nationwide retrospective surveys were conducted: medical histories were collected from patients aged 0 to 16 years who were hospitalized countrywide between 1996 and 2008. Hospital records for these patients were also reviewed. Nationwide training seminars on KD were conducted before each survey.

Results: For the nationwide surveys, the participation rates among all hospitals with pediatric wards were 97% and 94%. Inpatient medical histories from 1996 through 2008 were reviewed, and, among children younger than 16 years, 9 patients with KD were investigated. The age of KD patients ranged from 1.4 to 14 years; 7 of 9 patients were male. Six (67%) patients fulfilled all 6 clinical diagnostic criteria; the other 3 (33%) were defined as having KD based on the presence of 5 such criteria. Fever persisting 5 or more days, bilateral conjunctival congestion, and changes of the lips and oral cavity were the most common symptoms, and cervical lymphadenopathy was the least common symptom. Cardiac sequelae developed in 5 of the patients, 4 of whom were older than 10 years.

Conclusions: The results of these nationwide surveys reveal that KD cases do exist in Mongolia. However, knowledge of KD among Mongolian pediatricians is likely to be poor. Thus, there is a need to augment their understanding to improve management of KD patients. Further studies are crucial to clarify the epidemiologic characteristics of KD in Mongolia.

Key words: mucocutaneous lymph node syndrome; nationwide survey; Mongolia; children

INTRODUCTION

Kawasaki disease (KD; also known as acute infantile febrile mucocutaneous lymph node syndrome) was originally described as a distinct clinical entity in Japanese children by Dr. Tomisaku Kawasaki in 19671 and was first mentioned in the English literature in 1974.2 KD is now recognized as the leading cause of acquired heart disease among children in developed countries. It is an acute self-limited vasculitis of infancy and early childhood and is characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities (ie, reddening of palms and soles, indurative edema, and membranous desquamation), rash, and cervical lymphadenopathy. Although an infectious agent is suspected, the exact cause is unknown. However, considerable progress has been made in understanding the natural history of KD, and therapeutic interventions that reduce the immune-mediated destruction of the arterial wall have been developed.3 Coronary artery aneurysms or ectasia develop in approximately 20% to 30% of untreated children and can lead to ischemic heart disease or sudden death.4

KD patients have been identified in more than 60 countries, and KD has become the leading cause of acquired heart disease among children in developed countries. The reported
incidence of KD varies widely by country. Incidence is highest in Japan, and the numbers continue to rise, possibly due to heightened awareness of the condition. Recent reports from Japan show that the incidence of KD increased from 184.6 to 216.9 per 100,000 children aged 0 to 4 years from 2007 to 2008.5,6

The rate of KD in South Korean children younger than 5 years is estimated at 86.4/100,000, while the reported incidence in Taiwan is 66/100,000.7,8 The highest KD incidence in the United States was in Hawaii, 17.1/100,000.9 The overall incidence of KD in the United Kingdom was 8.1/100,000; however, it was reported to be 14.6/100,000 among children of parents from the Indian subcontinent.10

Located in the northern part of central Asia, Mongolia is a landlocked country bordered by Russia to the north and China to the south. With a total area of 1.6 million km2 and a population of 2.6 million as of 2008 (1.5 inhabitants per km2), Mongolia is one of the most sparsely populated countries in the world. In 2002, China reported a KD incidence of 36.8/100,000 children younger than 5 years.11 There has been no systematic study of KD in Mongolia. Therefore, we conducted nationwide surveys of KD incidence in Mongolia in 2005 and 2008.

METHODS

Study design and setting
We conducted a retrospective survey to investigate KD incidence among inpatients in Mongolia. Administratively, Mongolia is divided into 21 provinces; the capital, Ulaanbaatar city, comprises 9 districts. A total of 32 hospitals were included in the survey. This included the General Provincial Hospitals of all the provinces, the District Health Centers for all districts in Ulaanbaatar, the National Center for Communicable Diseases, and the Maternal and Children’s Research Center. These hospitals represent all pediatric wards in Mongolia in which children younger than 16 years are hospitalized.

Nationwide training seminar on KD
In collaboration with the Japan Kawasaki Disease Research Center (Tokyo 101-0041, Japan, Professor Tomisaku Kawasaki), we organized training seminars on KD diagnosis and treatment and our research methodology for pediatricians working throughout the country—including urban and rural areas. The training sessions were held in September in 2005 and 2008, ie, before the 2 national surveys, to provide information to pediatricians on the diagnosis and management of KD and standardized data collection procedures. Head physicians of the pediatric wards were invited to Ulaanbaatar for the training sessions. The cumulative participation rates were 94% and 100% in 2005 and 2008, respectively. The second seminar included pediatricians who had not attended the first seminar. An interview-based survey was used to assess the pediatrician’s knowledge of KD before training. The results of this pre-training survey revealed that almost 97% of Mongolian pediatricians had a poor understanding of KD. After each seminar, these newly trained pediatricians organized training for local doctors in their hospitals (”train the trainer”).

Data collection
After the first seminar, a nationwide survey of KD was initiated in collaboration with trained pediatricians. The medical histories of patients aged 0 to 16 years who were hospitalized during the period from 1996 through 2005 were retrieved in the first survey. The medical records of those who were hospitalized during the period from 2006 through 2008 were retrieved in the second survey to identify cases that satisfied the diagnostic guidelines of KD. The latest (5th) version of the “Diagnostic Guidelines of Kawasaki Disease” was translated into Mongolian and distributed to all hospitals, along with color photographs of the clinical features of KD. A classical diagnosis of KD is based on the presence of both a fever persisting at least 5 days and at least 4 of 5 other principal clinical features (Table 1). These principal clinical symptoms are bilateral conjunctival injection, changes in the lips and oral cavity, changes in the extremities, erythematous rash, and cervical lymphadenopathy. Our methodology accounted for the fact that, in general, not all clinical features of KD are present at a single time point and that a period of observation may thus be necessary before the diagnostic criteria are met. Patients with fever for at least 5 days and 4 of the other 5 principal clinical features received a diagnosis of KD. The presence of coronary artery disease was investigated by using 2-dimensional echocardiography or coronary angiography.

A brief survey questionnaire was provided to obtain information on KD patients and the details of their hospitalization. The questionnaire asked about demographics, KD symptoms, and cardiac complications.

The study protocols of the surveys were approved by the Institutional Review Board of the Health Sciences University of Mongolia.

### Table 1. Diagnostic criteria of Kawasaki disease

| Fever persisting at least 5 days |
| Presence of at least 5 principal features: |
| Changes in extremities |
| Acute—Erythema of palms, soles; edema of hands, feet |
| Subacute—Periungual peeling of fingers, toes in weeks 2 and 3 |
| Polymorphous exanthem |
| Bilateral bulbar conjunctival injection without exudate |
| Changes in lips and oral cavity—Erythema, lips cracking, strawberry tongue, diffuse injection of oral and pharyngeal mucosae |
| Cervical lymphadenopathy (>1.5 cm in diameter), usually unilateral |
Table 2. Age, sex, residence, and hospital of admission of observed KD patients

| Patient No. | Age (years) | Sex | Year and month of onset | Residence | Hospital | Diagnosis* | Treatment | Cardiac sequelae |
|-------------|-------------|-----|-------------------------|-----------|----------|------------|-----------|----------------|
| 1           | 10          | Girl | January, 1998           | Zavkhan province | General Provincial Hospital | Kawasaki disease | no | no | no |
| 2           | 13          | Boy  | September, 2005         | Tuv province | General Provincial Hospital | Cervical Lymphadenitis in left side | no | no | no |
| 3           | 10          | Boy  | March, 2002             | Sukhbaatar district, Ulaanbaatar | District Health Center | Toxic-allergic reaction of unknown etiology and dermatitis | no | no | no |
| 4           | 5           | Boy  | February, 2005          | Uvurkhangai province | General Provincial Hospital | Lupus erythematosus | no | no | yes |
| 5           | 1.4         | Boy  | November, 2007          | Dornogovi province | General Provincial Hospital | Viral infection | no | no | no |
| 6           | 14          | Boy  | March, 2000             | Baganuur district, Ulaanbaatar | Maternal and Children’s Research Center | Toxic-allergic reaction of unknown etiology and dermatitis | no | no | yes |
| 7           | 10          | Boy  | June, 2005              | Tuv province | Maternal and Children’s Research Center | Kawasaki disease, acute stage | yes | yes | yes |
| 8           | 11          | Boy  | November, 2008          | Songinokhairkhan district, Ulaanbaatar | Maternal and Children’s Research Center | Kawasaki disease, acute stage | yes | yes | yes |
| 9           | 1.6         | Girl | October, 2009           | Bayanzurkhi district, Ulaanbaatar | United Family Hospitals and Clinics, Beijing | Kawasaki disease | yes | yes | yes |

*Diagnosed during hospital admission.

^ Intravenous immunoglobulin.

There were no deaths.

RESULTS

Among all (n = 32) hospitals with pediatric wards, the participation rates in the 2 nationwide surveys were 97% and 94% in 2005 and 2008. In these surveys, a total of 241 705 inpatient medical histories were reviewed to identify cases that satisfied the diagnostic criteria for KD. Nearly 200 000 children were hospitalized in the general hospitals of rural provinces; the remaining children were hospitalized in the hospitals of Ulaanbaatar. By means of these surveys, we identified 9 patients aged 0 to 16 years who met the KD case definition. Of these, 4 were observed in the provinces of Dornod, Zavkhan, Uvurkhangai, and Tuv; 4 were hospitalized in Ulaanbaatar (3 in the Maternal and Children’s Research Center and 1 in Chingeltei District Health Center), and 1 case of KD that was not diagnosed in the hospitals of Ulaanbaatar. That patient received a KD diagnosis and was treated in Beijing, China.

As shown in Table 2, the age of our KD patients ranged from 1 year 4 months to 14 years, with a mean (± SD) of 8.4 ± 4.7 years. Seven (78%) of the 9 children were boys. Regarding place of residence, 4 (44%) were living in districts of Ulaanbaatar, and 5 resided in rural provinces. Five (56%) were hospitalized in winter and spring, and the others were hospitalized in summer and autumn.

Six (67%) patients fulfilled all 6 clinical criteria for KD; 2 (22%) patients had persistent fever plus 4 additional clinical KD criteria. Clinical symptoms of changes in the peripheral extremities and polymorphous exanthema were not found in the ninth patient, who was diagnosed in Beijing. Fever persisting 5 or more days, bilateral conjunctival congestion, and changes in lips and oral cavity were the most common symptoms and were observed in all patients. Cervical lymphadenopathy was the least common symptom and was found in 78% of KD patients in Mongolia.

Table 2 also shows diagnosis, treatment, cardiac sequelae, and outcome of children with KD. KD was correctly diagnosed in hospitals in 4 patients: 3 at the Maternal and Children’s Research Center—the largest children’s hospital in Mongolia—and 1 at a hospital in Zavkhan province. The condition of the remaining 5 cases (56%) was misdiagnosed as toxic-allergic reaction of unknown etiology, dermatitis, lupus erythematosus, or viral infection. The standard treatment for KD, namely, intravenous immunoglobulin (IVIG) and aspirin, was administered to only 3 (33%) children. Cardiac sequelae were documented in 56% of children who underwent echocardiography in hospitals in Ulaanbaatar. Unfortunately, echocardiography was not performed for the other patients because it was not available in rural hospitals. According to the medical records, no deaths occurred during hospitalization among the patients.

DISCUSSION

Before this study and educational undertaking for pediatricians, KD was unknown or under-identified as a disease entity in Mongolia. We conducted these retrospective surveys to determine (1) if KD was present, but undiagnosed, in Mongolia, (2) if Mongolian pediatricians had identified KD, but not reported it, or (3) if KD was not present in the Mongolian population.

In this survey, we abstracted medical records from all hospitals in which children are hospitalized in Mongolia. All other medical facilities in Mongolia have only outpatient pediatric clinics. Therefore, the results of these surveys may
Kawasaki Disease in Mongolia

Kawasaki Disease is an acute febrile illness of childhood characterized by fever, cervical lymphadenopathy, and other findings such as conjunctivitis, mouth ulcers, and rash. It is caused by an enterovirus typically known as enterovirus 71 (EV71). The disease is more common in Japan and other Asian countries, but cases have been reported worldwide. The disease is more common in children aged 6 months to 5 years, with boys being more frequently affected than girls. The incidence of Kawasaki Disease is estimated to be around 4248 hospitalizations for children younger than 5 years in the United States, compared to 10 times that in the United Kingdom and 30 times that in Mongolia. Worldwide, the annual incidence of Kawasaki Disease is 10 times that in the United States and 30 times that in Mongolia.

The first surveys were conducted in Mongolia in 1985 and 1991, and since then, several surveys have been conducted to determine the incidence of Kawasaki Disease. These surveys have shown that the disease is rare in Mongolia, with an estimated 4248 hospitalizations for Kawasaki Disease among children aged 0 to 16 years. The ratio of boys to girls is 3:2, and 85% of patients are younger than 5 years. Kawasaki Disease is uncommon in patients 9 years or older, with only 1% of cases being in patients aged 9 years or older. In our survey, the age of KD patients ranged from 1.4 to 14 years, and most were boys. Children with KD in Mongolia are older than those in Japan. However, recent reports have emphasized the occurrence of KD in older children, who may have a higher prevalence of cardiovascular complications related to late diagnosis.

Older age at onset of illness may be an independent risk factor for the development of coronary aneurysms in KD. Cardiac sequelae were observed in more than half of the present patients. This high proportion of cardiac sequelae could be related to the older age of our children at KD diagnosis and/or the lack of available treatment. Three children who received aspirin and IVIG developed coronary abnormalities, possibly due to delayed treatment. It should be noted that 97% of pediatricians countrywide were unaware of KD (only 1 pediatrician, from Ulaanbaatar, had knowledge of KD). Thus, IVIG therapy was not administered and echocardiography was not performed in suspected cases. In addition, it is possible that patients with mild or moderate KD symptoms were younger and were not referred to hospitals for admission due to lack of knowledge among physicians. Therefore, the present surveys might have missed many young patients with KD.

Aspirin and IVIG have been the main therapeutic regimen for Kawasaki Disease. Randomized, prospective, clinical trials in the United States in the 1980s established that IVIG was effective and safe, and that it reduced the rate of coronary artery lesions. Ideally, IVIG therapy should be initiated within the first 10 days of illness. Previously, the proportion of patients with cardiac sequelae was much higher (>20% until 1986) among patients younger than 1 year, as compared with other age groups. Since 1986, however, the incidence of coronary sequelae has been declining in this age group.

An infectious agent is strongly suspected as the cause of Kawasaki Disease. Analysis of the seasonal distribution of cases shows peak incidence in late winter/early spring. Thus, it seems likely that KD is associated with some widely distributed infectious agent. Nevertheless, no excess hospitalization for KD during winter and spring was found in Mongolia.

In this survey, we observed that fever persisting 5 days or longer, bilateral conjunctival congestion, and changes in lips and the oral cavity were the most common symptoms. Cervical lymphadenopathy was the least common among KD patients in Mongolia. Cervical lymphadenopathy was also identified as the least common of the principal clinical features in other studies.

A limitation of this study was that the surveys were based on a review of medical histories of hospitalized children, ie, there was no follow-up of children with KD. In
addition, young children with milder KD might have been underreported in this study because they were unlikely to have been hospitalized.

Nonetheless, this is the first report to identify KD patients in Mongolia, based on data from 2 nationwide retrospective surveys. In these surveys, all urban and rural hospitals with pediatric inpatient wards were included, and the medical history of every child younger than 16 years was reviewed to identify KD patients who were hospitalized throughout the country between 1996 and 2008.

In conclusion, the results of 2 nationwide surveys revealed that KD is present in Mongolia. Knowledge of KD among Mongolian pediatricians should be enhanced to increase diagnostic sensitivity and guarantee appropriate treatment of KD. In addition, further epidemiologic surveys are necessary to clarify the incidence and characteristics of KD in Mongolia.

ACKNOWLEDGMENTS

We would like to sincerely acknowledge the invaluable help and support of the Japanese Kawasaki Disease Research Center and Jichi Medical University, Japan for conducting the first surveys in Mongolia and for the first nationwide training of pediatricians in Kawasaki Disease diagnosis and management. We sincerely thank all the pediatricians who participated in these nationwide surveys. Particular thanks go to Dr. Bolormaa Tuvuudorj, from the Maternal and Child Health Research Medical Center, Ulaanbaatar city and other pediatricians who investigated the Kawasaki disease cases. We also acknowledge the kind contributions to this article of Professor Wayne Triner, Department of Emergency Medicine, Albany Medical College and Professor Louise-Anne McNutt, School of Public Health, University at Albany, State University of New York.

Conflicts of interest: None declared.

REFERENCES

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: clinical observation of 50 cases. Jpn J Allerg. 1967;16:178–222.
2. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome prevailing in Japan. Pediatrics. 1974;54:271–6.
3. Burns JC, Kushner HL, Bastian JF, Shike H, Shimizu C, Matsubara T, et al. Kawasaki disease: A brief history. Pediatrics. 2000;106:E27.
4. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110:2747–71.
5. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Chihara I, Aoyama Y, et al. Epidemiologic features of Kawasaki disease in Japan: Results of the 2007–2008 nationwide survey. J Epidemiol. 2010;20(4):302–7.
6. Nakamura Y, Yashiro M, Uehara R, Oki I, Watanabe M, Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: Results from the nationwide survey in 2005–2006. J Epidemiol. 2008;18:167–72.
7. Park YW, Han JW, Park IS, Kim CH, Yun YS, Cha SH, et al. Epidemiologic picture of Kawasaki disease in Korea, 2000–2002. Pediatr Int. 2005;47:382–7.
8. Chang LY, Chang IS, Lu CY, Chiang BL, Lee CY, Chen PJ, et al; Kawasaki Disease Research Group. Epidemiologic features of Kawasaki disease in Taiwan, 1996–2002. Pediatrics. 2004;114:e678–82.
9. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr. 2004;16:508–14.
10. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet. 2002;360:1197–202.
11. Huang GY, Ma XJ, Huang M, Chen SB, Huang MR, Gui YH, et al. Epidemiologic pictures of Kawasaki disease in Shanghai from 1998 through 2002. J Epidemiol. 2006 Jan;16(1):9–14.
12. Ministry of Health, Mongolia. Health indicators 2008. Ulaanbaatar, Mongolia; 2008.
13. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47:232–4.
14. Shulman ST, De Inocencio J, Hirsch R. Kawasaki disease. Pediatr Clin North Am. 1995;42:1205–22.
15. Morens DM, Anderson LJ, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics. 1980;65:21–5.
16. Singh S, Gupta MK, Bansal A, Kumar RM, Mittal BR. A comparison of the clinical profile of Kawasaki disease in children from Northern India above and below 5 years of age. Clin Exp Rheumatol. 2007;25:654–7.
17. Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics. 1995;95:475–9.
18. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr. 1995;126:524–9.
19. Stockheim JA, Innocentini N, Shulman ST. Kawasaki disease in older children and adolescents. J Pediatr. 2000;137:250–2.
20. Chang RK. Hospitalizations for Kawasaki disease among children in the United States, 1988–1997. Pediatrics. 2002;109:e87.
21. Momennah T, Sanatani S, Potts J, Sandor GG, Human DG, Patterson MW. Kawasaki disease in the older child. Pediatrics. 1998;102:e7.
22. Zhang T, Yanagawa H, Oki I, Nakamura Y. Factors relating to the cardiac sequelae of Kawasaki disease one month after initial onset. Acta Paediatr. 2002;91:517–20.
23. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma
globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. *N Engl J Med.* 1991;324:1633–9.

24. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. *J Pediatr.* 1997;131:888–93.

25. Han RK, Sinclair B, Newman A, Silverman ED, Taylor GW, Walsh P, et al. Recognition and management of Kawasaki disease. *CMAJ.* 2000;162:807–12.

26. Burgner D, Harnden A. Kawasaki disease: What is the epidemiology telling us about the etiology? *Int J Infect Dis.* 2005;9:185–94.